Daily Cardiology Research Analysis
Analyzed 137 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology studies stand out today: a head-to-head RCT shows the myosin inhibitor aficamten improves patient-reported health status more than metoprolol in obstructive hypertrophic cardiomyopathy; a pooled cohort analysis demonstrates ECG-based AI enhances heart failure risk prediction beyond a clinical risk score; and a prospective CMR study links infarct size, myocardial salvage, LVEF, and transmurality to 10-year mortality/heart failure after STEMI, while microvascular obstruction is not prognostic.
Research Themes
- Therapeutic innovation and patient-reported outcomes in hypertrophic cardiomyopathy
- AI-enabled risk stratification for heart failure prevention
- Imaging biomarkers predicting long-term outcomes after myocardial infarction
Selected Articles
1. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
In a double-blind head-to-head RCT of 175 symptomatic oHCM patients, aficamten produced a significantly greater 24-week improvement in KCCQ Overall Summary Score than metoprolol (+7.8 points) with more very large improvements and fewer deteriorations. SAQ Physical Limitation improved significantly with aficamten. These data support aficamten as an effective initial therapy prioritizing symptom relief and quality of life.
Impact: This is a rigorous head-to-head RCT demonstrating superior patient-reported health status with a disease-specific myosin inhibitor over standard beta-blockade in oHCM. It informs frontline therapeutic selection and centers patient-centered outcomes.
Clinical Implications: For symptomatic oHCM with LVOT obstruction, aficamten can be considered as an initial monotherapy option to achieve larger improvements in symptoms and quality of life compared with metoprolol, with routine use of KCCQ/SAQ to monitor response.
Key Findings
- Aficamten improved KCCQ-OSS by an adjusted +7.8 points versus metoprolol at 24 weeks (P < 0.001).
- Very large KCCQ improvements (≥20 points) occurred in 38.6% with aficamten vs 18.4% with metoprolol; fewer patients worsened with aficamten.
- SAQ Physical Limitation scores improved significantly with aficamten (+10.1 points), supporting functional benefit.
Methodological Strengths
- International, double-blind, randomized head-to-head design with active comparator
- Use of validated, serial patient-reported outcomes (KCCQ, SAQ) and prespecified clinically meaningful change categories
Limitations
- Modest sample size (n=175) and 24-week duration limit long-term safety/effect durability assessment
- Trial not powered for hard clinical events; generalizability to broader oHCM populations needs confirmation
Future Directions: Longer-term, event-driven trials evaluating clinical outcomes, safety, and sequencing/combination with other oHCM therapies; implementation studies integrating PROs into routine care.
BACKGROUND: The cardiac myosin inhibitor aficamten was significantly more effective than metoprolol at improving exercise tolerance in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a head-to-head, international, double-blind, randomized trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). Given the primary treatment goal to improve patients' health status, defining the incremental benefits of aficamten over metoprolol on patients' symptoms, function, and quality of life is needed. OBJECTIVES: In this study, the authors sought to compare patient-reported health status benefits of aficamten with metoprolol. METHODS: Adults with symptomatic oHCM (Kansas City Cardiomyopathy Questionnaire [KCCQ] Clinical Summary Score [CSS] ≤90; left ventricular outflow tract obstruction ≥30 mm Hg at rest or ≥50 mm Hg with Valsalva) were randomly assigned to 24 weeks of aficamten or metoprolol as monotherapy. Changes in KCCQ Overall Summary Score (OSS) and Seattle Angina Questionnaire Summary Score (SAQ-SS), collected serially throughout the trial, were compared between treatment groups at 24 weeks using linear regression, adjusted for randomization strata and baseline scores. Individual participant experiences were described by comparing categories of clinically meaningful within-participant change: ≤-5 (worse), >-5 to <+5 (no change), +5 to <+10 (small improvement), +10 to <+15 (moderate improvement), +15 to <+20 (large improvement), and ≥+20 points (very large improvement). RESULTS: Among 175 randomized patients, baseline health status scores were similar between treatment groups (n = 88 aficamten; n = 87 metoprolol). Aficamten, compared with metoprolol, resulted in a greater 24-week KCCQ-OSS improvement (adjusted between-group difference: +7.8 points; 95% CI: 3.3-12.3; P < 0.001), primarily driven by a greater proportion of aficamten-treated (38.6%) vs metoprolol-treated (18.4%) patients experiencing a very large (≥20 points) KCCQ-OSS improvement (number needed to treat = 4.9; 95% CI: 3.0-13.9), and a smaller proportion experiencing worsening health status (≤-5-point change: 6.8% vs 18.4%; number needed to harm = 8.6; 95% CI: 4.7-53.3). Nonsignificant SAQ-SS improvements with aficamten vs metoprolol (+4.6 points; 95% CI -0.3 to 9.5 points; P = 0.063) were driven by significantly larger improvements in the SAQ Physical Limitation scale (+10.1 points; 95% CI: 3.9-16.2 points; P = 0.001). CONCLUSIONS: Aficamten improved the health status of patients with symptomatic oHCM significantly more than did metoprolol, highlighting its potential as an effective initial therapeutic option. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM; NCT05767346).
2. Ten-year prognostic impact of cardiac magnetic resonance endpoints in patients with ST-segment elevation myocardial infarction.
In 811 STEMI patients with CMR at baseline and 3 months, infarct size, transmurality, myocardial salvage index, and LVEF independently predicted 10-year all-cause death or heart failure hospitalization, both acutely and at 3 months. Microvascular obstruction did not predict outcomes. These data refine which CMR biomarkers carry long-term prognostic weight.
Impact: This large, long-term prognostic study defines which CMR metrics robustly forecast a decade-long risk after STEMI and challenges the assumed prognostic role of MVO. It guides imaging targets, risk stratification, and surrogate endpoint selection.
Clinical Implications: Use infarct size, transmurality, MSI, and LVEF from acute and 3-month CMR to stratify long-term risk and tailor follow-up and therapies after STEMI; deprioritize MVO as a prognostic marker in routine practice.
Key Findings
- Infarct size (acute and 3-month) and transmurality were positively associated with 10-year death/HF hospitalization; higher MSI and LVEF were protective.
- Microvascular obstruction did not independently predict the composite outcome (adjusted HR 1.04; p=0.20).
- Prognostic associations were consistent at both acute and 3-month CMR time points.
Methodological Strengths
- Prospective imaging with standardized CMR at baseline and 3 months with long-term clinical follow-up
- Adjusted Cox regression with multiple CMR endpoints; registered trials cited
Limitations
- Observational prognostic analysis may be subject to residual confounding and selection bias
- Hazard ratios per unit change are modest; generalizability across centers and scanners requires consideration
Future Directions: Validate prognostic thresholds for IS/MSI/transmurality across vendors and populations; test whether therapy intensification guided by CMR metrics improves outcomes.
AIMS: The study aimed to investigate the importance of infarct size (IS), microvascular obstruction (MVO), and myocardial salvage index (MSI) on the 10-year outcome in patients with ST-segment elevation myocardial infarction (STEMI). METHODS AND RESULTS: Patients with STEMI had cardiac magnetic resonance (CMR) performed during admission and after three months to assess acute and three-month IS, MSI, left ventricular ejection fraction (LVEF), MVO and transmurality. Adjusted Cox regression models were used to investigate the association between CMR endpoints and all-cause mortality or hospitalization for heart failure 10 years after STEMI. A total of 811 patients had either acute or follow-up CMR performed. During median follow-up of 10.9 years, 173 (21%) patients died or were hospitalized for heart failure. Acute IS (adjusted hazard ratio (HR): 1.02; 95%-confidence interval (CI): 1.01-1.04; p=0.005), three-month IS (adjusted HR: 1.04; 95%-CI: 1.02-1.06; p<0.001), acute MSI (adjusted HR: 0.99; 95%-CI: 0.98-1.00; p=0.007), three-month MSI (adjusted HR: 0.99; 95%-CI: 0.98-1.00; p=0.004), acute LVEF (adjusted HR: 0.97; 95%-CI: 0.95-0.99; p=0.001), three-month LVEF (adjusted HR: 0.95; 95%-CI: 0.93-0.97; p<0.001), acute transmurality (adjusted HR: 1.01; 95%-CI: 1.00-1.02; p=0.024), and three-month transmurality (adjusted HR: 1.01; 95%-CI: 1.00-1.02; p=0.003) were all significant predictors of the composite outcome. MVO was not associated with the composite outcome (adjusted HR: 1.04; 95%-CI: 0.98-1.09; p=0.20). CONCLUSION: Smaller IS, smaller transmurality, higher MSI, and higher LVEF measured acutely and three months after STEMI were independently associated with lower all-cause mortality and/or hospitalization for heart failure within 10 years after STEMI, whereas MVO was not.Clinical trial registration: Registered with ClinicalTrials.gov (identifiers: NCT01435408 and NCT01960933).
3. Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis.
Across 14,126 participants from FHS, MESA, and CHS, ECG-AI models detecting systolic and diastolic dysfunction significantly improved discrimination and net reclassification over PREVENT-HF for 1–10 year HF risk. Positive ECG-AI screens identified individuals with 10–20-fold higher HF risk. This supports ECG-AI as a scalable tool for population-level HF prevention.
Impact: Demonstrates additive value of ECG-AI beyond a validated clinical risk score across multiple cohorts, enabling targeted prevention and efficient resource allocation.
Clinical Implications: Layer ECG-AI screening on clinical risk estimation (e.g., PREVENT-HF) to identify high-risk individuals for early echocardiography, biomarker testing, and preventive therapies; plan for implementation with attention to fairness and external validation.
Key Findings
- ECG-AI positivity conferred 10–20× higher incident HF risk than negative screens.
- Adding ECG-AI to PREVENT-HF improved net reclassification at 1–10 years (NRI ~0.086–0.125 at 10% threshold; ~0.327–0.403 at 20%).
- Composite ECG-AI positivity rate was 11.9%, supporting feasible targeting for preventive strategies.
Methodological Strengths
- Large pooled analysis across 3 landmark cohorts (FHS, MESA, CHS) with standardized evaluation on BioDataCatalyst
- Use of validated ECG-AI algorithms and rigorous metrics (C-statistics, NRI) across multiple time horizons
Limitations
- Retrospective pooled design with potential cohort heterogeneity; lack of prospective implementation outcomes
- Potential biases in AI performance across subgroups; external clinical workflow validation needed
Future Directions: Prospective pragmatic trials embedding ECG-AI in care pathways to test impact on HF incidence; fairness audits and calibration in diverse health systems.
BACKGROUND: Artificial intelligence applied to electrocardiograms (ECG-AI) offers a scalable approach to identify individuals at risk for heart failure (HF) and guide preventive interventions. OBJECTIVE: The purpose of this study was to assess whether ECG-AI designed to detect systolic and diastolic dysfunction enhances the prediction of incident HF over clinical risk estimation using the PREVENT-HF (Predicting Risk of Cardiovascular Disease EVENTs-Heart Failure) equation. METHODS: Baseline clinical and electrocardiogram data were pooled from the Framingham Heart Study, Multi-Ethnic Study of Atherosclerosis, and Cardiovascular Health Study. Participants with data sufficient for both ECG-AI and PREVENT-HF assessment were included. Analyses were performed on the National Heart, Lung, and Blood Institute BioDataCatalyst from July to September 2025. Risk of incident HF was estimated using previously validated ECG-AI algorithms that detect systolic (ECG-AI LEF) and diastolic (ECG-AI DD) dysfunction. Discrimination and reclassification were evaluated using Harrell's C-statistic and net reclassification improvement. RESULTS: Of 14,126 participants, positive screening rates were 2.9% for ECG-AI LEF, 11.1% for ECG-AI DD, 11.9% for the composite ECG-AI model, 25.1% for PREVENT-HF score ≥10%, and 5.8% for PREVENT-HF score ≥20%. Incident HF or death occurred in 7.7% and 15.1% of participants, respectively. Participants with positive composite ECG-AI screens at baseline had 10- to 20-fold higher risk of developing HF compared with those with negative screens. At 1, 3, 5, and 10 years, the addition of ECG-AI to PREVENT-HF yielded 1-directional net reclassification improvements ranging from 0.086 to 0.125 at a PREVENT-HF threshold of 10%, and 0.327 to 0.403 at a threshold of 20%. CONCLUSIONS: The addition of ECG-AI to PREVENT-HF improved discrimination of near-term HF risk. ECG-AI may enable population-level HF risk stratification and facilitate targeted prevention strategies.